Compare Mesoblast Limited (MESO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while YieldMax NVDA Option Income Strategy ETF trades at $12.51. The key difference: Mesoblast Limited is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MESO | NVDY | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $20.96 | $17.96 |
52-Week Low | $12.88 | $12.03 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
NVDY trades at $12.41, up 0.4% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The fund generates weekly dividends, with recent payouts ranging from $0.10 to $0.21 per share. News coverage highlights the trade-off between income and potential upside capture relative to NVIDIA's stock performance.
The outlook hinges on investor preference for consistent income versus capital appreciation. Risks include underperformance versus NVIDIA during strong rallies and fee drag. Sentiment is mixed, with some questioning the strategy's long-term value amid NVIDIA's volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
